表紙
市場調査レポート

生化学工業:製品パイプライン分析

Seikagaku Corporation - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256133
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
生化学工業:製品パイプライン分析 Seikagaku Corporation - Product Pipeline Review - 2015
出版日: 2015年11月18日 ページ情報: 英文 29 Pages
概要

生化学工業は医療機器メーカーで、特に複合糖質に関連した医薬品と医療機器の製造および販売を取り行っています。同社の製品には他に、複合糖質の主成分であるヒアルロン酸が含まれている関節機能改善剤などがあります。

生化学工業の基本情報

生化学工業の概要

  • 主要情報
  • 企業情報

生化学工業:R&Dの概要

  • 主な治療範囲

生化学工業:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

生化学工業:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ

生化学工業:薬剤プロファイル

  • condoliase
  • CF-101
  • hyaluronate sodium
  • SI-614
  • SI-613

生化学工業:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

生化学工業:最近のパイプライン動向

生化学工業:休止中のプロジェクト

生化学工業:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07780CDB

Summary

Global Markets Direct's, 'Seikagaku Corporation - Product Pipeline Review - 2015', provides an overview of the Seikagaku Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Seikagaku Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Seikagaku Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Seikagaku Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Seikagaku Corporation's pipeline products

Reasons to buy

  • Evaluate Seikagaku Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Seikagaku Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Seikagaku Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Seikagaku Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Seikagaku Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Seikagaku Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Seikagaku Corporation Snapshot
    • Seikagaku Corporation Overview
    • Key Information
    • Key Facts
  • Seikagaku Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Seikagaku Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Seikagaku Corporation - Pipeline Products Glance
    • Seikagaku Corporation - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Seikagaku Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Seikagaku Corporation - Drug Profiles
    • condoliase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hyaluronate sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cinhyaluronate sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SI-613
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Seikagaku Corporation - Pipeline Analysis
    • Seikagaku Corporation - Pipeline Products by Target
    • Seikagaku Corporation - Pipeline Products by Route of Administration
    • Seikagaku Corporation - Pipeline Products by Molecule Type
    • Seikagaku Corporation - Pipeline Products by Mechanism of Action
  • Seikagaku Corporation - Recent Pipeline Updates
  • Seikagaku Corporation - Dormant Projects
  • Seikagaku Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • piclidenoson
  • Seikagaku Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Seikagaku Corporation, Key Information
  • Seikagaku Corporation, Key Facts
  • Seikagaku Corporation - Pipeline by Indication, 2015
  • Seikagaku Corporation - Pipeline by Stage of Development, 2015
  • Seikagaku Corporation - Monotherapy Products in Pipeline, 2015
  • Seikagaku Corporation - Pre-Registration, 2015
  • Seikagaku Corporation - Phase III, 2015
  • Seikagaku Corporation - Phase II, 2015
  • Seikagaku Corporation - Pipeline by Target, 2015
  • Seikagaku Corporation - Pipeline by Route of Administration, 2015
  • Seikagaku Corporation - Pipeline by Molecule Type, 2015
  • Seikagaku Corporation - Pipeline Products by Mechanism of Action, 2015
  • Seikagaku Corporation - Recent Pipeline Updates, 2015
  • Seikagaku Corporation - Dormant Developmental Projects,2015
  • Seikagaku Corporation - Discontinued Pipeline Products, 2015
  • Seikagaku Corporation, Other Locations
  • Seikagaku Corporation, Subsidiaries

List of Figures

  • Seikagaku Corporation - Pipeline by Top 10 Indication, 2015
  • Seikagaku Corporation - Pipeline by Stage of Development, 2015
  • Seikagaku Corporation - Monotherapy Products in Pipeline, 2015
  • Seikagaku Corporation - Pipeline by Top 10 Target, 2015
  • Seikagaku Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Seikagaku Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Seikagaku Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top